Dry and Wet Age-Related Macular Degeneration – Landscape & Forecast – Disease Landscape & Forecast (G7)

Age-related macular degeneration (AMD) is a late-onset retinal disease that diminishes central visual acuity due to photoreceptor degeneration in the macula leading to vision impairment and blindness. Wet AMD is currently treated with historical mainstays such as off-label Avastin and Eylea, as well as newer entrants to the market including Roche / Chugai’s Vabysmo and Regeneron / Bayer / Santen’s Eylea HD. The wet AMD market will see further fragmentation with the introduction of emerging therapies, that mostly aim to further extend treatment intervals. These include three gene therapies (i.e., Regenxbio / AbbVie’s sura-vec (formerly ABBV-RGX-314), Adverum’s ixo-vec, and 4DMT’s 4D-150), and three long-acting TKIs (i.e., EyePoint Pharmaceutical’s Duravyu, Ocular Therapeutix’s Axpaxli, and Clearside Biomedical’s CLS-AX). By contrast, the management of geographic atrophy (GA) is currently limited to two complement system inhibitors in the United States, Apellis’s Syfovre and Astellas’s Izervay. We expect the launch of J&J Innovative Medicines’ JNJ-1887 in the United States by the end of our forecast and the launch of Izervay in Japan in 2026.

Questions answered

• How will the wet AMD treatment algorithm change as new products such as Vabysmo and Eylea HD gain traction? To what extent will they capitalize on the need for therapies with longer dosing intervals?
• How will biosimilars of Eylea impact market dynamics in the different geographies?
• How receptive are retinal specialists to novel gene therapy approaches and to emerging therapies for wet AMD and GA?
• What are U.S. retinal specialists’ impressions of novel GA treatments?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.